| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7630653 | Journal of Pharmaceutical and Biomedical Analysis | 2015 | 9 Pages |
Abstract
- A 23-gene signature was developed to predict chemoresistance of breast cancers.
- The signature could define chemoresistance in ovarian, prostate cancers, as well as leukemia.
- The signature could predict clinic outcomes in breast cancers.
- Decitabine was found to target the signature and inhibit chemoresistance.
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Dong-Xu He, Yu-Dong Xia, Xiao-Ting Gu, Jian Jin, Xin Ma,